[HTML] frontiersin.org

[HTML][HTML] Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand?

A Rizzo, AD Ricci, A Di Federico, G Frega… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …
被引用次数：94 相关文章

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

A Rizzo, AD Ricci, A Di Federico, G Frega… - Frontiers in …, 2021 - cir.nii.ac.jp
抄録< jats: p> Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed
malignancy worldwide, still representing an important cause of cancer-related death. Over …
[HTML] nih.gov

[HTML][HTML] Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

A Rizzo, AD Ricci, A Di Federico, G Frega… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

A Rizzo, AD Ricci, A Di Federico… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

A Rizzo, AD Ricci, A Di Federico, G Frega… - Frontiers in …, 2021 - europepmc.org
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …